BRPI0416319A - composto, composição farmacêutica, métodos de tratamento ou prevenção da dor, das sìndromes, e de doença, e, métodos de administrar anestesia local, e para a neuroproteção sob condições isquêmicas - Google Patents
composto, composição farmacêutica, métodos de tratamento ou prevenção da dor, das sìndromes, e de doença, e, métodos de administrar anestesia local, e para a neuroproteção sob condições isquêmicasInfo
- Publication number
- BRPI0416319A BRPI0416319A BRPI0416319-2A BRPI0416319A BRPI0416319A BR PI0416319 A BRPI0416319 A BR PI0416319A BR PI0416319 A BRPI0416319 A BR PI0416319A BR PI0416319 A BRPI0416319 A BR PI0416319A
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- pain
- compound
- alone
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Psychiatry (AREA)
- AIDS & HIV (AREA)
- Biotechnology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
Abstract
"COMPOSTO, COMPOSIçãO FARMACêUTICA, MéTODOS DE TRATAMENTO OU PREVENçãO DA DOR, DAS SìNDROMES, E DE DOENçA, E, MéTODOS DE ADMINISTRAR ANESTESIA LOCAL, E PARA A NEUROPROTEçãO SOB CONDIçõES ISQUêMICAS". Compostos de triazol substituído representados pelas Fórmulas ou seus sais farmaceuticamente aceitáveis. As composições farmacêuticas compreendem uma quantidade eficaz dos presentes compostos, ou sozinhos, ou em combinação com um ou mais outros compostos terapeuticamente ativos, e um carreador farmaceuticamente aceitável. Métodos de tratar de condições associadas com, ou causadas por, atividade do canal de sódio, incluindo, por exemplo, a dor aguda, a dor crónica, a dor visceral, a dor inflamatória, a dor neuropática, a enxaqueca, a dor de cabeça, a cefaléia da enxaqueca, a epilepsia, a síndrome de intestino irritável, a neuropatia diabética, a esclerose múltipla, a depressão maníaca e o distúrbio bipolar, compreendem administrar uma quantidade eficaz dos presentes compostos, ou sozinhos, ou em combinação com um ou mais outros compostos terapeuticamente ativos. Um método de administrar a anestesia local compreende administrar uma quantidade eficaz de um composto da presente invenção, ou isoladamente, ou em combinação com um ou mais outros compostos terapeuticamente ativos, e um carreador farmaceuticamente aceitável.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51889003P | 2003-11-10 | 2003-11-10 | |
PCT/US2004/037280 WO2005047270A2 (en) | 2003-11-10 | 2004-11-05 | Substituted triazoles as sodium channel blockers |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0416319A true BRPI0416319A (pt) | 2007-01-09 |
Family
ID=34590316
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0416319-2A BRPI0416319A (pt) | 2003-11-10 | 2004-11-05 | composto, composição farmacêutica, métodos de tratamento ou prevenção da dor, das sìndromes, e de doença, e, métodos de administrar anestesia local, e para a neuroproteção sob condições isquêmicas |
Country Status (17)
Country | Link |
---|---|
US (2) | US20090074890A1 (pt) |
EP (1) | EP1694654B1 (pt) |
JP (1) | JP2007510741A (pt) |
KR (1) | KR20060123739A (pt) |
CN (1) | CN1922156A (pt) |
AT (1) | ATE500234T1 (pt) |
AU (1) | AU2004289694B2 (pt) |
BR (1) | BRPI0416319A (pt) |
CA (1) | CA2545254A1 (pt) |
DE (1) | DE602004031667D1 (pt) |
IL (1) | IL175522A0 (pt) |
IS (1) | IS8438A (pt) |
NO (1) | NO20062676L (pt) |
NZ (1) | NZ547044A (pt) |
RU (1) | RU2372339C2 (pt) |
WO (1) | WO2005047270A2 (pt) |
ZA (1) | ZA200603583B (pt) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY142651A (en) * | 2003-03-18 | 2010-12-15 | Merck Sharp & Dohme | Biaryl substituted triazoles as sodium channel blockers |
BRPI0416319A (pt) * | 2003-11-10 | 2007-01-09 | Merck & Co Inc | composto, composição farmacêutica, métodos de tratamento ou prevenção da dor, das sìndromes, e de doença, e, métodos de administrar anestesia local, e para a neuroproteção sob condições isquêmicas |
GB0525068D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
GB0603008D0 (en) * | 2006-02-14 | 2006-03-29 | Portela & Ca Sa | Method |
KR100808551B1 (ko) | 2006-12-01 | 2008-03-03 | 한국생명공학연구원 | 트리아졸 유도체를 유효성분으로 함유하는 대사성 질환 예방 및 치료용 약학적 조성물 |
DK2118077T3 (en) | 2007-02-08 | 2015-03-09 | Synta Pharmaceuticals Corp | Triazole compounds that modulate HSP90 ACTIVITY |
EP2129225B1 (en) * | 2007-04-03 | 2012-12-05 | E. I. Du Pont de Nemours and Company | Substituted benzene fungicides |
JP5613565B2 (ja) * | 2007-10-25 | 2014-10-22 | リバルシオ コーポレイション | 細胞膜媒介細胞内シグナル伝達を調節するための組成物および方法 |
EP2207669A4 (en) * | 2007-10-25 | 2011-11-02 | Revalesio Corp | BACTERIOSTATIC OR BACTERIOZIDE COMPOSITIONS AND METHOD |
WO2009067621A1 (en) | 2007-11-21 | 2009-05-28 | Decode Genetics Ehf | Biaryl pde4 inhibitors for treating pulmonary and cardiovascular disorders |
EP2222638A2 (en) * | 2007-11-21 | 2010-09-01 | Decode Genetics EHF | Biaryl pde4 inhibitors for treating inflammation |
US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
JP2013518085A (ja) | 2010-02-01 | 2013-05-20 | ノバルティス アーゲー | CRF−1受容体アンタゴニストとしてのピラゾロ[5,1b]オキサゾール誘導体 |
WO2011092293A2 (en) | 2010-02-01 | 2011-08-04 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
ES2527849T3 (es) | 2010-02-02 | 2015-01-30 | Novartis Ag | Derivados de ciclohexilamida como antagonistas del receptor de CRF |
AR086554A1 (es) | 2011-05-27 | 2014-01-08 | Novartis Ag | Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina |
EP2852591A1 (en) | 2012-05-03 | 2015-04-01 | Novartis AG | L-malate salt of 2, 7 - diaza - spiro [4.5]dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19816880A1 (de) * | 1998-04-17 | 1999-10-21 | Boehringer Ingelheim Pharma | Neue Diphenyl-substituierte 5-Ring-Heterocyclen, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel |
AR029489A1 (es) * | 2000-03-10 | 2003-07-02 | Euro Celtique Sa | Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento |
AU4589701A (en) * | 2000-03-24 | 2001-10-08 | Cocensys Inc | Aryl substituted pyrazoles, triazoles and tetrazoles, and the use thereof |
AR037233A1 (es) * | 2001-09-07 | 2004-11-03 | Euro Celtique Sa | Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento |
US20060183897A1 (en) * | 2003-03-18 | 2006-08-17 | Chakravarty Prasun K | Biaryl substituted triazoles as sodium channel blockers |
MY142651A (en) * | 2003-03-18 | 2010-12-15 | Merck Sharp & Dohme | Biaryl substituted triazoles as sodium channel blockers |
BRPI0416319A (pt) * | 2003-11-10 | 2007-01-09 | Merck & Co Inc | composto, composição farmacêutica, métodos de tratamento ou prevenção da dor, das sìndromes, e de doença, e, métodos de administrar anestesia local, e para a neuroproteção sob condições isquêmicas |
-
2004
- 2004-11-05 BR BRPI0416319-2A patent/BRPI0416319A/pt not_active Application Discontinuation
- 2004-11-05 EP EP04800897A patent/EP1694654B1/en active Active
- 2004-11-05 WO PCT/US2004/037280 patent/WO2005047270A2/en active Application Filing
- 2004-11-05 RU RU2006120426/04A patent/RU2372339C2/ru not_active IP Right Cessation
- 2004-11-05 US US10/578,950 patent/US20090074890A1/en not_active Abandoned
- 2004-11-05 AT AT04800897T patent/ATE500234T1/de not_active IP Right Cessation
- 2004-11-05 CN CNA2004800329352A patent/CN1922156A/zh active Pending
- 2004-11-05 DE DE602004031667T patent/DE602004031667D1/de active Active
- 2004-11-05 NZ NZ547044A patent/NZ547044A/en unknown
- 2004-11-05 KR KR1020067009120A patent/KR20060123739A/ko not_active Application Discontinuation
- 2004-11-05 JP JP2006539729A patent/JP2007510741A/ja not_active Ceased
- 2004-11-05 AU AU2004289694A patent/AU2004289694B2/en not_active Ceased
- 2004-11-05 CA CA002545254A patent/CA2545254A1/en not_active Abandoned
- 2004-11-10 US US10/985,592 patent/US7459475B2/en active Active
-
2006
- 2006-05-04 IS IS8438A patent/IS8438A/is unknown
- 2006-05-05 ZA ZA200603583A patent/ZA200603583B/xx unknown
- 2006-05-09 IL IL175522A patent/IL175522A0/en unknown
- 2006-06-09 NO NO20062676A patent/NO20062676L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
ATE500234T1 (de) | 2011-03-15 |
IL175522A0 (en) | 2006-09-05 |
IS8438A (is) | 2006-05-04 |
US7459475B2 (en) | 2008-12-02 |
JP2007510741A (ja) | 2007-04-26 |
US20090074890A1 (en) | 2009-03-19 |
KR20060123739A (ko) | 2006-12-04 |
CN1922156A (zh) | 2007-02-28 |
EP1694654B1 (en) | 2011-03-02 |
NZ547044A (en) | 2010-05-28 |
AU2004289694A1 (en) | 2005-05-26 |
NO20062676L (no) | 2006-08-10 |
US20060020006A1 (en) | 2006-01-26 |
RU2372339C2 (ru) | 2009-11-10 |
EP1694654A2 (en) | 2006-08-30 |
CA2545254A1 (en) | 2005-05-26 |
ZA200603583B (en) | 2007-08-29 |
DE602004031667D1 (de) | 2011-04-14 |
WO2005047270A3 (en) | 2005-09-22 |
WO2005047270A2 (en) | 2005-05-26 |
RU2006120426A (ru) | 2007-12-27 |
AU2004289694B2 (en) | 2010-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IS8438A (is) | Setin tríasól sem natríum gangahemla | |
CA2519252A1 (en) | Biaryl substituted triazoles as sodium channel blockers | |
RU2329062C2 (ru) | Способы и композиции для снятия боли | |
JP2007530694A5 (pt) | ||
FI965156A (fi) | Aryylisulfonamido-substituoidut hydroksaamihapot matriisimetalloproteinaasi-inhibiittoreina | |
WO2008057802A3 (en) | Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same | |
RU95106649A (ru) | Производные бензимидазола в качестве непептидильных антагонистов рецепторов тахикинина, способ получения, фармацевтическая композиция | |
WO2007075524A3 (en) | Substituted piperidines as calcium channel blockers | |
BRPI0514553A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para inibir o receptor de histamina h3 em um mamìfero, para o tratamento de um distúrbio do sistema nervoso, para o tratamento de obesidade e para o tratamento de um distúrbio ou doença, e, uso de um composto ou um sal do mesmo | |
EA200300172A1 (ru) | Метод обезболивания | |
BR0313352A (pt) | Composto, composições farmacêuticas, método para a produção de um composto, método para o tratamento, prevenção ou a melhora de um distúrbio e método para o tratamento de um mamìfero | |
WO2007145922A3 (en) | Benzazepinones as sodium channel blockers | |
WO2004011477A3 (en) | 6,11-4-carbon bridged ketolides | |
BRPI0607701A2 (pt) | composto ou um sal, éster, solvato, estereoisÈmero, tautÈmero ou pró-droga farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de uma quantidade antibacterialmente eficaz de um composto junto com um veìculo farmaceuticamente aceitável, e, método de preparação de um composto | |
HK1108633A1 (en) | Stable pharmaceutical composition of fluoroether compound for anesthetic use, method for stabilizing a fluoroether compound, use of stabilizer agent for precluding the degradation of a fluoroether compound | |
WO2005046700A1 (ja) | アミノグリコシド系抗生物質およびブロムフェナクを含有する水溶液製剤 | |
RU2006127422A (ru) | Антимикробные консерванты для достижения мультидозовых рецептур с использованием бета-циклодекстринов для жидких лекарственных форм | |
JP2007510741A5 (pt) | ||
RU2011100106A (ru) | Замещенные бензимидазолы для лечения нейрофиброматоза | |
ES2188940T3 (es) | Administracion topica de premafloxacina para el tratamiento de enfermedades bacterianas sistemicas. | |
MX2022011240A (es) | Azálidos de urea inmunomoduladores. | |
WO2008038092A3 (en) | Substituted piperidinophenyl oxazolidinones | |
DOP2004000850A (es) | Triazoles sustituidos con biarilo como bloqueantes del canal de sodio | |
BR0315231A (pt) | Compostos com base em glicose com afinidade para p-seletina | |
WO2004000864A3 (en) | 11-c-substituted ketolides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B25D | Requested change of name of applicant approved |
Owner name: MERCK SHARP AND DOHME CORP. (US) Free format text: ALTERADO DE: MERCK AND CO., INC. |
|
B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
B11T | Dismissal of application maintained [chapter 11.20 patent gazette] |